Bruton's Tyrosine Kinase and Immune Tolerance in Type 1 Diabetes
布鲁顿酪氨酸激酶和 1 型糖尿病的免疫耐受
基本信息
- 批准号:8042106
- 负责人:
- 金额:$ 37.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-01-27 至 2015-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAgammaglobulinaemia tyrosine kinaseAmino AcidsAntigen PresentationAntigensAutoantibodiesAutoantigensAutoimmune DiabetesB cell repertoireB-Cell DevelopmentB-Lymphocyte SubsetsB-LymphocytesBindingBiological AssayCell physiologyCellsClinicalComplement 3d ReceptorsComplexDependenceDevelopmentDiabetes MellitusDiseaseDisease ProgressionEffectivenessEmployee StrikesEventGoalsImmune ToleranceImmunoglobulin GInbred NOD MiceIndividualInsulinInsulin-Dependent Diabetes MellitusInterventionKnock-outLeadLinkMature B-LymphocyteMediatingModelingMolecularMusOutcomePhosphotransferasesPlayProcessPropertyReceptor SignalingReceptors, Antigen, B-CellRoleSignal PathwaySignal TransductionSignaling MoleculeSpecificityStagingSystemT-LymphocyteTestingTherapeutic InterventionTransgenic MiceTransgenic ModelTransgenic OrganismsTyrosine Kinase DomainTyrosine Kinase Inhibitoradapter proteinantigen bindingautoreactive B cellautoreactivitybaseisletmouse modelnovelpreventreconstitutionresearch studyresponsesmall moleculetool
项目摘要
DESCRIPTION (provided by applicant): Type 1 diabetes (T1D) results from a complex cascade of events that breaks immune tolerance and culminates in the destruction of islet 2 cells. B lymphocytes (B cells) play a critical role in disease development, probably via antigen-presentation to pathogenic T cells. B cell contribution to the development of diabetes depends upon multiple factors, including loss of tolerance to self antigen. This tolerance is mediated by cellular responses to antigen-binding via the B cell receptor (BCR). Bruton's tyrosine kinase (BTK) is a central component of the BCR-triggered signaling pathway. Understanding cell signaling components underlying B cell-driven diabetes development will advance the field toward specific targeting of pathogenic B cells. We have introgressed btk-deficiency onto the nonobese diabetic (NOD) mouse model of T1D, and found that this results in significant protection against the development of diabetes. In addition, btk-deficiency interferes with B cell related breaches of immune tolerance, as evidenced by the loss of insulin-specific IgG autoantibodies in wild type NOD mice, and reduction of insulin-binding B cells in a transgenic anti-insulin BCR model. The specific hypothesis underlying this proposal is that BTK-mediated propagation of BCR signals contributes to 1) selection and survival of autoreactive B lymphocytes, and 2) disease- promoting functional properties of these B cells. To understand the mechanisms of action of BTK in breaking B lymphocyte tolerance and promoting disease in autoimmune diabetes, we propose to: 1) discover how BTK participates in the selection and retention of autoreactive B lymphocytes, using use new tools that include a conditional, B cell-specific BTK knockout model and small molecule BTK- inhibitors, 2) determine which domains of the BTK molecule are responsible for autoreactive B lymphocyte selection and function, by systematically restoring independent components responsible for the kinase and linking functions, and 3) investigate the mechanisms of btk-deficiency in preventing T1D by examining effects on B cell subsets, antigen-presenting outcomes, and regulatory parameters. This project has direct clinical importance in understanding how BCR-signaling supports the selection, survival and function of autoreactive B cells in T1D, as a necessary step in developing therapeutic interventions.
PUBLIC HEALTH RELEVANCE: Autoreactive B lymphocytes are essential to the development of type 1 diabetes. The goal of this project is to understand how B cell signaling, mediated by Bruton's tyrosine kinase, supports the breach of immunologic tolerance that occurs in this disease. These discoveries will provide new avenues of intervention for the specific targeting of autoreactive, pathogenic B cells.
描述(由申请人提供):1型糖尿病(T1D)是由破坏免疫耐受并最终破坏胰岛2细胞的复杂级联事件引起的。B淋巴细胞(B细胞)在疾病发展中起关键作用,可能是通过抗原呈递给病原性T细胞。B细胞对糖尿病发展的贡献取决于多种因素,包括对自身抗原耐受性的丧失。这种耐受性是由通过B细胞受体(BCR)对抗原结合的细胞应答介导的。布鲁顿酪氨酸激酶(BTK)是BCR触发的信号通路的核心组分。了解B细胞驱动的糖尿病发展的细胞信号成分将推动该领域朝着特异性靶向致病性B细胞的方向发展。我们已经将btk缺陷基因渗入到T1D的非肥胖糖尿病(NOD)小鼠模型中,并发现这导致了对糖尿病发展的显着保护。此外,btk缺陷会干扰与B细胞相关的免疫耐受破坏,正如野生型NOD小鼠中胰岛素特异性IgG自身抗体的丧失以及转基因抗胰岛素BCR模型中胰岛素结合B细胞的减少所证明的那样。该提议背后的具体假设是BTK介导的BCR信号的传播有助于1)自身反应性B淋巴细胞的选择和存活,和2)这些B细胞的疾病促进功能特性。为了了解BTK在破坏B淋巴细胞耐受性和促进自身免疫性糖尿病疾病中的作用机制,我们建议:1)发现BTK如何参与自身反应性B淋巴细胞的选择和保留,使用包括条件性B细胞特异性BTK敲除模型和小分子BTK抑制剂的新工具,2)通过系统地恢复负责激酶和连接功能的独立组分,确定BTK分子的哪些结构域负责自身反应性B淋巴细胞选择和功能,和3)通过检查对B细胞亚群、抗原呈递结果和调节参数的影响来研究btk缺陷在预防T1D中的机制。该项目在理解BCR信号传导如何支持T1D中自身反应性B细胞的选择、存活和功能方面具有直接的临床重要性,这是开发治疗干预措施的必要步骤。
公共卫生相关性:自身反应性B淋巴细胞对1型糖尿病的发展至关重要。这个项目的目标是了解布鲁顿酪氨酸激酶介导的B细胞信号传导如何支持这种疾病中发生的免疫耐受的破坏。这些发现将为特异性靶向自身反应性、致病性B细胞提供新的干预途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peggy L Kendall其他文献
Peggy L Kendall的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peggy L Kendall', 18)}}的其他基金
Bruton's Tyrosine Kinase and Immune Tolerance in Type 1 Diabetes
布鲁顿酪氨酸激酶和 1 型糖尿病的免疫耐受
- 批准号:
10059473 - 财政年份:2019
- 资助金额:
$ 37.94万 - 项目类别:
Bruton's Tyrosine Kinase and Immune Tolerance in Type 1 Diabetes
布鲁顿酪氨酸激酶和 1 型糖尿病的免疫耐受
- 批准号:
8583319 - 财政年份:2011
- 资助金额:
$ 37.94万 - 项目类别:
Bruton's Tyrosine Kinase and Immune Tolerance in Type 1 Diabetes
布鲁顿酪氨酸激酶和 1 型糖尿病的免疫耐受
- 批准号:
8215848 - 财政年份:2011
- 资助金额:
$ 37.94万 - 项目类别:
Bruton's Tyrosine Kinase and Immune Tolerance in Type 1 Diabetes
布鲁顿酪氨酸激酶和 1 型糖尿病的免疫耐受
- 批准号:
8386669 - 财政年份:2011
- 资助金额:
$ 37.94万 - 项目类别:
Bruton's Tyrosine Kinase and Immune Tolerance in Type 1 Diabetes
布鲁顿酪氨酸激酶和 1 型糖尿病的免疫耐受
- 批准号:
8776292 - 财政年份:2011
- 资助金额:
$ 37.94万 - 项目类别:
Bruton's Tyrosine Kinase and Immune Tolerance in Type 1 Diabetes
布鲁顿酪氨酸激酶和 1 型糖尿病的免疫耐受
- 批准号:
8886719 - 财政年份:2011
- 资助金额:
$ 37.94万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 37.94万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 37.94万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 37.94万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 37.94万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 37.94万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 37.94万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 37.94万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 37.94万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 37.94万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 37.94万 - 项目类别:














{{item.name}}会员




